| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
EU Conditional Marketing Approval |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Treatment of organ failure associated with Sepsis | $33B | Completed | Phase IIb Initiation Q4-4 2020 | ||||
| Treatment of organ failure associated with COVID-19 | $1B | Completed | Phase II Ongoing | ||||
| Prevention of post-Bone Marrow Transplantations (BMT) complications | $3B | Phase IIa Completed, Phase II Initiation 2022 | |||||
| Solid tumor “immune checkpoint” microenvironment modulation | $4B | Completed | |||||
Pipelinemonimono2020-12-20T09:36:33+00:00
